Swiss Life Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Swiss Life Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Buy	+3,601	New	+$263K	﹤0.01%	1225

Other funds holding SYRE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Swiss Life Asset Management's SYRE Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 3,601 shares worth $320K. The stake represents ﹤0.01% of the portfolio and ranks #1225 among its holdings.

125 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Swiss Life Asset Management held 3,601 shares of Spyre Therapeutics worth $320K as of Q2 2026.
Spyre Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1225 holding.
125 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.